Diabetes is a metabolic disease, wherein the body is either unable to secret insulin (type 1 diabetes) or is unable to utilize the generated insulin (type 2 diabetes).
This report contains market size and forecasts of Non Insulin Anti diabetes Drugs in Global, including the following market information:
Global Non Insulin Anti diabetes Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non Insulin Anti diabetes Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non Insulin Anti diabetes Drugs include Sanofi, Abbott, AstraZeneca, Eli Lilly, Roche, GlaxoSmithKline, Johnson & Johnson and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non Insulin Anti diabetes Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non Insulin Anti diabetes Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non Insulin Anti diabetes Drugs Market Segment Percentages, by Type, 2021 (%)
Oral Drugs
Injectable Drugs
Global Non Insulin Anti diabetes Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non Insulin Anti diabetes Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Non Insulin Anti diabetes Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non Insulin Anti diabetes Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non Insulin Anti diabetes Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non Insulin Anti diabetes Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Abbott
AstraZeneca
Eli Lilly
Roche
GlaxoSmithKline
Johnson & Johnson
Novartis